N/A
Manufactured by LXO US Inc.
26,137 FDA adverse event reports analyzed
Last updated: 2026-04-15
ALISKIREN HEMIFUMARATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by LXO US Inc.. The most commonly reported adverse reactions for ALISKIREN HEMIFUMARATE include NAUSEA, BLOOD PRESSURE INCREASED, HEADACHE, FATIGUE, ASTHENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALISKIREN HEMIFUMARATE.
Out of 5,933 classified reports for ALISKIREN HEMIFUMARATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 26,137 FDA FAERS reports that mention ALISKIREN HEMIFUMARATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include NAUSEA, BLOOD PRESSURE INCREASED, HEADACHE, FATIGUE, ASTHENIA, FALL. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list LXO US Inc. in connection with ALISKIREN HEMIFUMARATE. Always verify the specific product and NDC with your pharmacist.